PARSIPPANY, N.J., March 28, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, announced today that it will release 2016 year end and fourth quarter financial results on Wednesday, March 29, 2017 after the stock market closes. The Company will also host an investor conference call on Wednesday at 4:30 pm EDT.
Investors, analysts and members of the professional financial community are invited to participate in the call by dialing one of the below numbers:
Domestic: 1-877-397-0272 International: 1-719-325-4751
Conference ID: 6214396
A replay of the call will be available for two weeks from 7:30 p.m. ET on March 29, 2017, until 11:59 p.m. ET on April 12, 2017. The number for the replay is (844) 512-2921, or (412) 317-6671 for international calls; the passcode for the replay is 6214396. The audio recording of the call will also be available on the Company's website within 24 hours of the call.
About Interpace Diagnostics Group, Inc.
Interpace is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace's mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, please visit Interpace Diagnostics' website at www.interpacediagnostics.com
CONTACTS:
Interpace DiagnosticsInvestor Relations:
Paul Kuntz[email protected]
Advertisement
Investors, analysts and members of the professional financial community are invited to participate in the call by dialing one of the below numbers:
Advertisement
Domestic: 1-877-397-0272 International: 1-719-325-4751
Conference ID: 6214396
A replay of the call will be available for two weeks from 7:30 p.m. ET on March 29, 2017, until 11:59 p.m. ET on April 12, 2017. The number for the replay is (844) 512-2921, or (412) 317-6671 for international calls; the passcode for the replay is 6214396. The audio recording of the call will also be available on the Company's website within 24 hours of the call.
About Interpace Diagnostics Group, Inc.
Interpace is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace's mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, please visit Interpace Diagnostics' website at www.interpacediagnostics.com
CONTACTS:
Interpace DiagnosticsInvestor Relations:
Paul Kuntz[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/interpace-diagnostics-group-announces-timing-of-earnings-release-and-investor-conference-call-300430683.html
SOURCE Interpace Diagnostics Group, Inc.
